Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma

JA Roberts, P Bradding, KM Britten, AF Walls, S Wilson, C Gratziou, ST Holgate, PH Howarth
European Respiratory Journal 1999 14: 275-282; DOI:
JA Roberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Bradding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KM Britten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AF Walls
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Wilson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Gratziou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ST Holgate
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PH Howarth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma. Both in vitro and animal studies suggest that it may have anti-inflammatory activities of benefit in this disease. To assess this directly, the effects of 6 weeks' treatment with salmeterol on indices of clinical activity, airway dysfunction and inflammation in subjects with stable atopic asthma were investigated. In a double blind study, asthmatic patients were randomized to 6 weeks' treatment with either salmeterol 50 microg twice daily (n=14) or placebo (n=12). They underwent bronchoscopy with bronchoalveolar lavage (BAL) and bronchial biopsy immediately before starting treatment and again after 6 weeks. Treatment with salmeterol improved clinical indices of asthma activity, but there were no changes in BAL differential cell counts or mediator levels, and no change in T-cell numbers or activation status. In the biopsy specimens there were no changes in numbers of inflammatory cells, sub-basement membrane collagen deposition or mast cell degranulation. Regular treatment with salmeterol improves clinical indices of asthma but has no effect on the underlying inflammatory process. These findings strengthen guideline recommendations that long-acting beta2-agonists should not be prescribed as sole antiasthma medication.

PreviousNext
Back to top
Vol 14 Issue 2 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma
JA Roberts, P Bradding, KM Britten, AF Walls, S Wilson, C Gratziou, ST Holgate, PH Howarth
European Respiratory Journal Aug 1999, 14 (2) 275-282;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma
JA Roberts, P Bradding, KM Britten, AF Walls, S Wilson, C Gratziou, ST Holgate, PH Howarth
European Respiratory Journal Aug 1999, 14 (2) 275-282;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volume reduction surgery versus conservative treatment in severe emphysema
  • Inhaled isotonic alkaline versus saline solution and radioaerosol clearance in chronic cough
  • Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
Show more Clinical Trial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society